LONDON, July 10, 2026 /PRNewswire/ — Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) today closed its previously announced exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of…

Read the full release →

News provided by PR Newswire.